Efficacy of taxanes as adjuvant treatment of breast cancer: A review and meta-analysis of randomised clinical trials

Clinical and Translational Oncology

Volumn 13, Issue 7, 2011, Pages 485-498

  Ginés, Jordi ^a   Sabater, Eliazar ^b   Martorell, Clara ^a   Grau, María ^b   Monroy, Marta ^a   Casado, Miguel A ^b  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

Author keywords

Adjuvant treatment; Breast cancer; Docetaxel; Meta analysis; Paclitaxel; Taxanes

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID;

ARTICLE; BLOOD TOXICITY; BLOODSTREAM INFECTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; BREAST TUMOR; FEMALE; META ANALYSIS (TOPIC); REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 80255135728     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0686-x     Document Type: Article

References (61)

1. Mondial International Agency for Research on Cancer (World Health Organization), Lyon. Available at: www-dep.iarc.fr/
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
3. Bonadonna G, Moliterni A, Zambetti M et al (2005) 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217-220 (Pubitemid 40188068)
4. Bria E, Nistico C, Cuppone F et al (2006) Benefits of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 106:2337-2344 (Pubitemid 43787656)
5. Ferguson T, Wilcken N, Vagg R et al (2007) Taxanes for adjuvant treatment of early cancer. Cochrane Database Syst Rev 4:CD004421
6. De Laurentiis M, Cancello G, D'Agostino D et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44-53
7. Buzdar AU, Singletary SE, Valero V et al (2002) Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073-1079 (Pubitemid 34517642)
8. Gianni L, Baselga J, Eiermann W et al (2009) Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 27:2474-2481
9. Bear HD, Anderson S, Smith SE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027 (Pubitemid 46622110)
10. Critical Appraisal Skills Programme Espãol (CASPe) Calculadora para metaanálisis. Available at: www.redcaspe.org
11. Bucher HC, Guyatt GH, Griffith LE et al (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683-691 (Pubitemid 27341818)
12. Wells GA, Sultan SA, Chen L et al (2009) Indirect evidence: indirect treatment comparison in meta-analysis. Canadian Agency for Drugs and Technologies in Health, Ottawa. Available at: http://www.cadth.ca/index.php/en/ itc-user-guide/download-software
13. Martín M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Eng J Med 352:2302-2313 (Pubitemid 40740554)
14. Goldstein LJ, O'Niell A, Sparano JA et al (2008) Concurrent doxorubicin plus docetaxel is not more efective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 26: 4092-4099
15. Martín M, Lluch A, Seguí MA et al (2008) Multicenter, randomized phase III study of adjuvant chemotherapy for high risk, node-negative breast cancer comparing TAC with FAC: five-year efficacy analysis of the GEICAM 9805 trial. J Cin Oncol ASCO Annual Meeting Proceedings 26[Suppl 1]:abstract 542
16. Del Mastro L, Costantini M, Durando A et al (2008) Cyclophosphamide, epirubicin, and 5-fluorouracil versus epurubicin plus paclitaxel in nodepositive early breast cancer: a randomized phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group. J Cin Oncol ASCO Annual Meeting Proceedings 26[Suppl]:abstract 516
17. Kümmel S, Krocker J, Kohls A et al (2006) Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer 94:1237-1244
18. Roche H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-5671 (Pubitemid 46631307)
19. Martín M, Rodríguez-Lescure A, Ruiz A et al (2008) Randomized phase III trial of fluorouracil, epirubicin and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100:805-814 (Pubitemid 351809668)
20. Fountzilas G, Skarlos D, Dafni U et al (2005) Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Group. Ann Oncol 16:1762-1771 (Pubitemid 41631238)
21. Burnell M, Levine MN, Chapman JA et al (2010) Cyclophosphamide, epirubicin and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28:77-82
22. Ellis P, Barret-Lee P, Johnson L et al (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open label, phase III, randomised controlled trial. Lancet 373:1681-1692
23. Polyzos A, Malamos N, Boukovinas I et al (2010) FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat 119:95-104
24. Nitz U, Huober J, Lisboa B et al (2008) Superiority of sequential docetaxel over standard FE100C in patients with intermediate risk breast cancer: survival results of the randomized intergroup phase III trial EC-Doc. 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, abstract 78
25. Francis P, Crown J, di Leo A et al (2008) Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 100:121-133 (Pubitemid 351480565)
26. Henderson C, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983 (Pubitemid 46594124)
27. Mamounas E, Bryant J, Lembersky B et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686-3696
28. Cognetti F, de Laurentiis M, de Matteis A et al (2008) Sequential epirubicin-docetaxel-CMF as adjuvant therapy for node-positive early stage breast cancer: update results of the TAXit216 randomized trial. 33rd ESMO Congress, Stockholm, Sweden, abstract 1820
29. Jones S, Holmes FA, O'Shaughnessy J et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177-1183
30. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/ Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439 (Pubitemid 46594092)
31. Hudis C, Citron ML, Berry D et al (2005) Five year follow-up of INT C9741: dose-dense chemotherapy is safe and effective. 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, abstract 41
32. Swain SM, Jeong JH, Geyer CE et al (2008) NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel, and cyclophosphamide in women with operable, node positive breast cancer. 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, abstract 75
33. Eiermann W, Pienkowski T, Crown J et al (2008) BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide followed by docetaxel (AC-T) in women with HER2 normal and axillary lymph node positive early breast cancer. 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, abstract 77
34. Poole CJ, Hiller L, Howard H et al (2008) tAnGo: a randomized phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamidebased, adjuvant chemotherapy for women with early-stage breast cancer. J Clin Oncol ASCO Annual Meeting Proceedings 26[Suppl 1]:abstract 506
35. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R et al (2009) Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology 10:1145-1151
36. Sparano JA, Wang M, Martino S et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Eng J Med 358:1663-1671 (Pubitemid 351549913)
37. Watanabe T, Kuranami K, Inoue K et al (2009) Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxane with 8-cycle taxane as adjuvant therapy for nodepositive breast cancer: Results of N-SAS-BC02 trial. J Cin Oncol ASCO Annual Meeting Proceedings 27(15S):abstract 516
38. Engelsman E, Kligin JC, Rubens RD et al (1991) "Classical" CMF versus 3-weekly intravenous CMF schedule in postmenopausal women with advanced breast cancer: an EORTC breast cancer co-operative group phase III trial (10808). Eur J Cancer 27:966-970
39. Gennari A, Sormani M, Costantini M et al (2006) Anthracycline regimens versus CMF in the adjuvant treatment of early cancer: a matter of difference. J Clin Oncol ASCO Annual Meeting Proceedings 18[Suppl]:abstract 569
40. Fisher B, Brown AM, Dimitrov NV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast Cancer and Bowel Project B-15. J Clin Oncol 8:1483-1496 (Pubitemid 20301179)
41. Fisher B, Anderson S, Tan-Chiu E et al (2001) Tamoxifen and chemotherapy for axillary nodenegative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast Cancer and Bowel Project B-23. J Clin Oncol 19: 931-942 (Pubitemid 32176267)
42. Martín M, Villar A, Sole-Calvo A et al (2003) Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophsphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 14:833-842 (Pubitemid 36827198)
43. Hutchins LF, Green SJ, Ravdin PM et al (2005) Randomized controlled trial of cyclophosphamide, methotrexate and fluorouracil versus cyclophosphamide, doxorubicin and fluorouracil with and without tamoxifen for high risk, node-negative breast cancer: treatment results of Intergroup protocol INT-0102. J Clin Oncol 23:8313-8321
44. Levine MN, Pritchard KI, Bramwell VH et al (2005) Randomized trial comparing cyclophosphamide, epirubicin and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA.5. J Clin Oncol 23:5166-5170 (Pubitemid 46224025)
45. Poole CJ, Earl HM, Hiller L et al (2006) Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Eng J Med 355:1851-1862 (Pubitemid 44664643)
46. Fumoleau P, Kerbrat P, Romestaing P et al (2003) Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 21:298-305 (Pubitemid 46606159)
47. Bonneterre J, Roche H, Kerbrat P et al (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year followup results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23:2686-2693 (Pubitemid 46179458)
48. Perez DJ, Harvey VJ, Robinson BA et al (1991) A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9:2148-2152
49. NCCN Clinical Practice Guidelines in Oncology Breast Cancer v.1.2010. Available at: www.nccn.org
50. Del Mastro L, Dozin B, Aitini E et al (2008) Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings for two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group. Ann Oncol 19:299-307 (Pubitemid 351201711)
51. Giménez Poderós T, Gaminde Inda I, Iruin Sanz A et al (2005) Taxanos en el tratamiento adyuvante del cáncer de mama con ganglios positivos: metanálisis. Farm Hosp 29:75-85 (Pubitemid 40872226)
52. Jones SE, Erban J, Overmoyer B et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551
53. Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III of weekly compared with every-three-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER2 overexpressors and random assignment to trastuzumab or not in HER2 non-overexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649
54. Early and locally advanced breast cancer. Diagnosis and treatment. NICE clinical guideline 80. National Institute for Health and Clinical Excellence, February 2009
55. López-Tarruella S, Martín M (2009) Advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res 11:204
56. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502 (Pubitemid 43854964)
57. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685 (Pubitemid 41170290)
58. de Ronde JJ, Hannemann J, Halfwerk H et al (2010) Concordance of clinical and molecular breast cancer subtyping in the context of the preoperative chemotherapy response. Breast Cancer Res Treat 119:119-126
59. Hayes DF, Thor AD, Dressler LG et al (2007) HER2 response to paclitaxel in node-positive breast cancer. N Eng J Med 357:1496-1506 (Pubitemid 47572635)
60. Penault-Llorca P, André F, Sagan C et al (2009) Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2809-2815
61. Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an inmunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168-11